AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01811732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delafloxacin
Description: Delafloxacin
Study NCT01811732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin
Study NCT01811732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aztreonam
Description: Aztreonam
Study NCT01811732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01811732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03808233 — intervention group
Intervention type: OTHER
Intervention: ACTIVE mini
Description: the ACTIVE-mini, is a non-invasive method of recording movement in an infant using a KINECT camera system. This camera is positioned over a resting infant and measures natural movement over a two minute time period.
Study NCT02392026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Gel
Description: Metronidazole Vaginal Gel 1.3% administered via applicator
Study NCT03280407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Radio-chemotherapy with 50.4 Gy in 28 fractions to tumor and regional lymph nodes concomitantly with capecitabine 825 mg/m2 b.i.d
Study NCT03280407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen (oxaliplatin/leucovorin/5FU)
Description: Six cycles: Oxaliplatin 85 mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1 and 5FU 2400 mg/ m2 over 46-48 hours day 1-3, repeated every two weeks.
Study NCT03280407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX (oxaliplatin/capecitabine)
Description: Four cycles: Oxaliplatin 130 mg/m2 day 1 and capecitabine 1000 mg/m2 b.i.d. days 1-14, repeated every 3 weeks.
Study NCT01105520 — intervention group
Intervention type: PROCEDURE
Intervention: Diagnostic
Description: SCIM Spinal Cord Independence Measure ASIA scale American Spinal Injury Association
Study NCT04784130 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Respondents will complete activity logs (step count, using pedometer) and surveys (two items from the Summary of Diabetes Self-care activities measure) for physical activity.
Study NCT04784130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Respondents will complete activity logs (step count, using pedometer) and surveys (two items from the Summary of Diabetes Self-care activities measure) for physical activity.
Study NCT02951520 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new technique for lower limb nerve blocks using a single skin puncture (SOFT block)
Description: The patients will be in supine position. The block needle will be inserted at the inguinal crease (medial to the femoral vein) and advanced towards the femoral nerve, then redirected towards the obturator nerve (deep to the pectineus muscle). Lastly, it will be redirected posteriorly towards the sciatic nerve (deep to the quadratus femoris muscle). A ropivacaine-lidocaine-epinephrine mixture will be used to block these nerves. The block success rate (painless surgery), performance time and patient discomfort will be recorded.
Study NCT04792619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bobath Approach
Description: The patients in both groups were treated with the exercise program according to the Bobath concept was planned taking the functional needs of the survivors into account, including stretching and facilitation of latissimus dorsi muscle, facilitation of abdominal muscles, placing exercises, training of lumbar spine stabilizers, functional reach of shoulder in different directions. Five sessions of about an hour each were provided to the patients
Study NCT04792619 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bobath Approach
Description: The patients in both groups were treated with the exercise program according to the Bobath concept was planned taking the functional needs of the survivors into account, including stretching and facilitation of latissimus dorsi muscle, facilitation of abdominal muscles, placing exercises, training of lumbar spine stabilizers, functional reach of shoulder in different directions. Five sessions of about an hour each were provided to the patients
Study NCT04792619 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isometric scapular exercises
Description: Isometric scapular exercises were performed to the patients included to the study group in a sitting position and at 900 of the shoulder flexion and 900 of the shoulder abduction. The patients were exercised by a physiotherapist using isometric contraction in protraction and retraction by a physiotherapist. Isometric contractions lasted 5 seconds and each exercise was repeated 2x15 times. One minute rest period was given between sets
Study NCT04784130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Adherence
Description: Respondents will provide information on their medication adherence using a survey (questionnaire - MMAS-8).
Study NCT04784130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Modification
Description: Respondents will complete food logs and surveys (three items from the Summary of Diabetes Self-care activities measure) for dietary intake.
Study NCT01249417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: I.M. (in the muscle) injection on day 1 of a single treatment cycle.
Study NCT01249417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: I.M. injection on day 1 of a single treatment cycle.
Study NCT02760719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebulized 3% hypertonic solution
Description: already described
Study NCT01480388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/JNJ-39758979 (300 mg/d)
Description: Form = tablet, route = oral adminstration placebo once daily from Week 0 to Week 24 followed by JNJ-39758979 300 mg once daily from Week 24 to Week 48.
Study NCT01480388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39758979 (10 mg)
Description: Form = tablet, route = oral adminstration once daily up to 48 weeks
Study NCT01480388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39758979 (30 mg)
Description: Form = tablet, route = oral adminstration once daily up to 48 weeks
Study NCT01480388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39758979 (100 mg)
Description: Form = tablet, route = oral adminstration once daily up to 48 weeks
Study NCT01480388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39758979 (300 mg)
Description: Form = tablet, route = oral adminstration once daily for 48 weeks
Study NCT00976326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: The dose level will be one single dose of 0.4 units per kg body weight injected s.c. (subcutaneously, under the skin)
Study NCT00369915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Study NCT02907567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT1812
Description: Active study drug
Study NCT02907567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-active study drug
Study NCT04137328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: 0.6mg/day in the first week, if there is no obvious discomfort, 1.2mg/day in the second week, subcutaneous injection, lasting for 3 months
Study NCT04137328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin
Description: Add or adjust insulin (when basic insulin is preferred for those who do not use insulin, such as those who have already used insulin, adjust the dosage or program according to the condition, inject subcutaneously) for 3 months
Study NCT03183505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anyu Peibo
Description: Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper
Study NCT03183505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule, twice per day, oral after breakfast and supper
Study NCT01383655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: i.v. magnesium 40mg/kg in 20 min
Study NCT01383655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl
Study NCT01430468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glenoid Positioning System
Description: Design and fabrication of patient specific instrument for placement of a guide pin to be used to aid in bone preparation for placement of a metaglene and its fixation screws or anatomic glenoid component
Study NCT04484116 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intraoperative Paratohormone
Description: Three IOPTH determinations were withdrawn: at anesthetic induction (PTH0), 15 minutes (PTH15), and 30 minutes (PTH30) after completion gland resection. Another sample was taken 24 hours after the procedure (PTH24), values \<150pg/mL defined a successful surgery and patients were assigned to the successful or unsuccessful group. IOPTH drop was analyzed to predict successful surgery with drops of 70% and 90% at 15 and 30 minutes.
Study NCT00974259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Management protocol based on pBrO2 and ICP values.
Description: For patients who experience falls in pBrO2 below 20 mm Hg, a hierarchical treatment algorithm will be instituted, adapted from published recommendations49. In principle, episodes requiring therapy will fall into one of 4 scenarios (scenario A, B, C, and D, defined in figure 7), which will require different management strategies. The treatment protocol depends on which type of episode is being treated. Treatment is triggered by abnormalities in either ICP (> 20 mm Hg) or pBrO2 (\< 20 mm Hg) are noted. Elevations in ICP above 20 mm Hg or decline in pBrO2 below 20 mm Hg for more than 5 minutes will trigger a treatment intervention. Treatment is directed to an episode. Patients may start in one type of episode and move to another. Therapy will depend on which type of episode they are in at any given time.
Study NCT00974259 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Management protocol based on ICP values only.
Description: For the patients randomized to ICP treatment alone, only Scenario A and Scenario B episodes are relevant.
Study NCT04508127 — intervention group
Intervention type: DEVICE
Intervention: Spinal cord stimulation
Study NCT03202017 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Expiratory Muscle Strength Training (EMST)
Description: EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.
Study NCT03202017 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMST + Lung Volume Recruitment (LVR)
Description: EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.~LVR is a technique to increase cough function that is performed with a resuscitation bag fitted with a mouthpiece and a one-way valve. The bag is used to expand the lungs, after which the patient makes a voluntary cough. Half of the participants will perform the LVR technique in addition to the ESMT technique.
Study NCT00354575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herb: CCH1
Description: 1.5/3.0/4.5gm powder per day for mild/moderate/severe constipation
Study NCT00354575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chinese Herb: CCH1
Description: 1.5/3.0/4.5gm powder per day for mild/moderate/severe constipation
Study NCT03551327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Intervention plus information
Description: The intervention will include six sessions with a therapist, each separated by two weeks. During the two weeks between sessions, participants will work on the goals identified during the sessions. At the final session, the participants will agree how to maintain any improvements in fatigue. Then there will be a review phone call about 4-6 weeks after completion of the intervention, to check on progress and to offer ongoing encouragement to continue with the changes that have been made during the intervention. The intervention can be delivered by video conferencing as well as by phone.
Study NCT03551327 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Active Comparator: Information only
Description: Participants in this arm will be provided with information about fatigue.
Study NCT01425619 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Cream of Macrogol cetostearyl ethers
Description: The cream will be applied on the volar aspect of both arms for 1 hour
Study NCT01425619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cream of Lidocaine 2.5 %.and Prilocaine 2.5 %
Description: 1-2 gr. of the cream will be applied on the volar aspect of the second arm; for 1 hour
Study NCT01425619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care and treatment from a medical clown
Description: Medical clown will entertain the children before, during and after performing the skin test. Placebo cream will be applied on both arms.
Study NCT01425619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care and treatment from a medical clown
Description: Medical clown will entertain the children, placebo cream will be applied on one arm and anesthetic cream on the second arm
Study NCT03794700 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hospice Decision Aids
Description: Paper and video hospice decision aid
Study NCT03532659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active video game
Description: Among the 20 municipal schools, two will be selected between those with 298 or more students (corresponding to the third quartile of the number of students per school). Next will be selected the school in which the adolescents will be submitted to intervention, and the students from the other school will be control. The intervention will aim to promote physical exercise through active video game XBOX 360 with Kinect. The game selected will be Just Dance, to allow the participation of up to four students at the same time. In addition, a gamification protocol will be performed to increase the adolescents engagement in the exercise.
Study NCT02120287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will receive bevacizumab (10 mg/kg) one day before and then at day 14 followed by10 mg/kg/day every 14 days until progression.
Study NCT02120287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopy (MRS)
Description: Subjects will have MRS prior to BZ-SRS.
Study NCT02120287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Border Zone Stereotactic Radiosurgery (BZ-SRS)
Description: The 'border zone' of the tumor will be targeted by SRS in a single session.
Study NCT04314635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief family engagement intervention for CHR
Description: The individual sessions, done with the caregiver and the teen separately, include a review of symptoms and a qualitative interview exploring treatment priorities, attitudes, and perceived barriers. The first family session focuses on psychoeducation. The second family session focuses on motivational enhancement, to promote ongoing engagement in services after discharge, including outpatient treatment and case management through the CSC.
Study NCT04314635 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: The TAU group will receive treatment as usual on the adolescent inpatient unit. This includes individual therapy, psychiatric care, skills groups, and family therapy meetings.
Study NCT01148329 — intervention group
Intervention type: DEVICE
Intervention: Coronary stenting
Description: The PROMUS™ Element™ Everolimus Eluting Coronary Stent System is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. The treated lesion length should be less than the nominal stent length (8 mm, 12 mm, 16 mm, 20 mm, 24 mm, 28 mm, 32 mm, 38mm) with a reference vessel diameter of 2.25 mm - 4.0 mm.
Study NCT00872755 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nissen
Description: Laparoscopic Nissen Fundoplication
Study NCT00872755 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastropexy
Description: posterior gastropexy
Study NCT02519140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cook Medical EMR Gel
Description: Cook Medical EMR Gel will be injected submucosally into ex-vivo gastric or colonic tissue specimens
Study NCT02310100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TactiCath Quartz treatment
Study NCT01546532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLX030
Description: RLX030 as intravenous infusion for 24 hours.
Study NCT01546532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of Placebo over 24 hours
Study NCT01190059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ex vivo lung perfusion with Steen Solution™
Description: The circuit is primed with 2,000cc Steen Solution™. At one hour of EVLP, 500 cc of circulated perfusate was removed and replenished with 500 cc of fresh perfusate. After that, 250 cc of perfusate was exchanged every hour.
Study NCT03112824 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ashwagandha Root Extract Capsule
Description: Participants will take one 300 mg capsule of Ashwagandaha Root Extract orally twice a day for 12 weeks.
Study NCT03112824 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Participants will take one placebo capsule orally twice a day for 12 weeks.
Study NCT03339739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric mandibular exercises
Description: daily video guided three-minutes routine in 21 days (days of OC consumption) of soft clenching over three millimeters silicone bars bilaterally on molars
Study NCT03339739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic mandibular exercises
Description: daily video guided three-minutes routine in 21 days (days of OC consumption) of isotonic dynamic contraction over calibrated cloth pegs on central incisors
Study NCT03339739 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Counseling group
Description: subjects included in this group get an education brochure about the disorder and receive no further interventions
Study NCT01518153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 by vein on Day -6 to -3.
Study NCT01518153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m\^2 by vein on Day -2.
Study NCT01518153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 50 mg by vein on Day -1.
Study NCT01518153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Reduced intensity stem cell transplant on Day 0.
Study NCT01518153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35.
Study NCT01518153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6.
Study NCT01518153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 \* 10/L for 3 consecutive days.
Study NCT01518153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Dose Donor T-Cells
Description: Planned Donor Lymphocyte Infusion CD3+ cells: 3 \* 106 CD3+ cells/kg between Day +56 and +64.
Study NCT01518153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Dose Donor T-Cells
Description: Planned Donor Lymphocyte Infusion CD3+ cells: 1 \* 107 CD3+ cells/kg between Day +56 and +64.
Study NCT02327351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological: TCR alfa beta T cell depletion
Study NCT00229138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC-MPS, Tacrolimus
Study NCT00229138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-MPS, Tacrolimus
Study NCT00743431 — intervention group
Intervention type: DRUG
Intervention: Caelyx (Pegylated Lyposomal Doxorubicin)
Description: Pegylated Lyposomal Doxorubicin, 50 mg/m2 every 4 weeks for 6 cycles.
Study NCT02473289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg
Description: Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.
Study NCT02473289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo on Day 1, 28 and 56.